Navigation Links
Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
Date:3/31/2009

ANNAPOLIS, Md., March 31 /PRNewswire-FirstCall/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new mechanism of action data for Valortim(R) were presented at the Keystone Symposia on Molecular and Cellular Biology Conference on Dendritic Cells, March 29-April 3, 2009 in Banff, Alberta.

The data were presented by Dr. Alan S. Cross, Professor of Medicine and Dr. Subhendu Basu, Research Associate, University of Maryland School of Medicine, in a poster presentation on March 30th entitled MAb-Enhanced, Human Dendritic Cell-Mediated Adaptive Immune Response to B. Anthracis. Valortim(R) is a fully human anti-toxin monoclonal antibody being developed in conjunction with Medarex, Inc. for the prevention and treatment of inhalational anthrax.

Previous mechanism of action data have shown that in addition to inhibiting anthrax toxin, Valortim(R) augments the immune system's ability to kill anthrax bacilli. In an in vitro mouse macrophage model, Valortim(R) enhanced the killing of B. anthracis (anthrax) by macrophages in a time and dose-dependent manner.

The new data presented by Drs. Cross and Basu build on this initial information in the mouse model by demonstrating that Valortim(R) can enhance the killing of anthrax by human dendritic cells.

Dr. Cross remarked, "These latest studies using human immune cells provide additional evidence of the role of Valortim(R) in enhancing the killing of B. anthracis. We hypothesize that Valortim(R) may protect against lethal anthrax infection by its toxin neutralization activity that allows the development of a potent human dendritic cell-mediated adaptive response that rids the host of viable bacteria."

D
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
(Date:9/30/2014)... Ind. , Sept. 30, 2014  The orthopedic specialists ... the nation,s No. 6 orthopedic group by US News ... Active Adults," a series of free, public seminars to ... all over the world come to see the knee ... procedures are now available at Munster Specialty Surgery Center. ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... , LITTLE FALLS, N.J., Dec. 2 ... the results for its first quarter ended October 31, 2009 on ... to discuss the results at 11:00 AM ET. Participating in ... President and CEO; Seth R. Segel, Executive Vice President; Craig A. ...
... , , CENTENNIAL, Colo., Dec. 2 ... bone and soft tissue allografts for use in surgical procedures ... substitutes, today announced its sponsorship of a truly iconic symbol ... Life float in the January 1, 2010 Tournament of Roses ...
Cached Medicine Technology:Cantel Medical Corp. to Hold Conference Call to Discuss Results for its First Quarter Ended October 31, 2009 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 3
(Date:9/30/2014)... With the flu season upon ... day, it’s a perfect time to announce Jan-Pro’s ... is an electro-static disinfectant delivery system that dries ... missed with spray-on disinfectant applicators. , The EnviroShield ... electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... A group of Americans is headed to a remote ... unchecked, could create a catastrophic, global pandemic. No, it’s not ... Rogers, the Executive Director the Eugene Bell Foundation and his ... most think mankind conquered long ago: tuberculosis. , “Tuberculosis, mostly ... the comeback in several countries - what’s especially disconcerting is ...
(Date:9/30/2014)... September 30, 2014 Two revolutionary procedures now ... treatment of gum disease a far less painful and ... , “If you’ve ever felt electric shock waves surge through ... a cold beverage, it’s possible you already know the impact ... is a general dentist in West Palm Beach, and a ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Medicare should cover low-dose ... risk for the disease, a coalition of more than ... which includes the Lung Cancer Alliance, the Society of ... Cancer Society and the American Society of Clinical Oncology, ... the U.S. Centers for Medicare & Medicaid Services (CMS). ...
(Date:9/30/2014)... has made progress in reducing the stigma associated with ... post-traumatic stress disorder, but more improvement is still needed, ... efforts of both the Defense Department and the Veterans ... members still do not seek needed care for ... effort to promote treatment as a way to reduce ...
Breaking Medicine News(10 mins):Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3
... Dec. 12 (HealthDay News) -- Severe side effects may be ... taking drugs that can help prevent a tumor,s return, a ... gap between what these breast cancer patients tell their doctors ... to the study authors from Northwestern University in Chicago. ...
... Henry Ford Hospital have found that one-quarter of severe asthma ... medication as prescribed. Moreover, an asthma attack was only ... their prescribed dose, according to the study. Patients often ... of symptoms. Henry Ford researchers say this is the ...
... myeloma are both malignant diseases that arise from lymphocytes, ... nodes and the bone marrow. Although considerable progress has ... remain a significant challenge for patients and their hematologists. ... lymphoma and myeloma will be presented today at the ...
... is available in German . Seabirds often ... as fleas and ticks, take advantage of this ideal habitat ... can transmit blood parasites like avian malaria to the birds. ... and a team of international colleagues have investigated whether this ...
... How should insights about the brain affect the course of ... the issuing of a sentence? This was ... at the Society for Neuroscience,s "Neuroscience 2011." Titled "The Brain ... how advances in neuroscience are both challenging and assisting the ...
... HealthDay Reporter , SUNDAY, Dec. 11 (HealthDay News) -- ... with severe sickle cell anemia can also help young children ... sickle cell anemia younger than 4 years old who took ... hospital admissions, illnesses with fever and need for transfusions, the ...
Cached Medicine News:Health News:Side Effects Cause Many Older Women to Drop Breast Cancer Drugs 2Health News:Improved medication use could reduce severe asthma attacks 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 3Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 4Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 5Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 6Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 7Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 8Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 9Health News:Only few seabird species contract avian malaria 2Health News:Only few seabird species contract avian malaria 3Health News:The brain on trial 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3
The fat loss formula's key ingredient of 2.0% aminophylline works by penetrating deep into the skin where it causes the body fat cells to shrink, resulting in up to 2 inches of body fat loss....
... VelaSmooth is the first ... device with the revolutionary elos ... Radio Frequency and Infrared Light ... with suction to reduce the ...
... was designed with the physician, staff ... you the best economy exam room ... does not skimp on patient comfort. ... can easily position patients so that ...
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
Medicine Products: